Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease

Antiviral Therapy

Volumn 12, Issue 4, 2007, Pages 553-558

  Samri, Assia ^a,b,c   Goodall, Ruth ^d   Burton, Catherine ^e   Imami, Nesrina ^e   Pantaleo, Giuseppe ^f   Kelleher, Anthony ^g   Poli, Guido ^h   Gotch, Frances ^e   Autran, Brigitte ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NELFINAVIR; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HIV ANTIGENS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 34447263328     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
3. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-2567.
4. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279:930-937.
5. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109-2117.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-733.
7. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
8. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180:76-86.
9. Rinaldo CR, Jr., Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-336.
10. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - 10 October 2006. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
11. Plana M, Martinez C, Garcia F, et al. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr 2002; 29:429-434.
12. Barreiro P, Soriano V, Casas E, Gonzale z-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002; 16:245-249.
13. Sullivan AK, Burton CT, Nelson MR, et al. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Scand J Immunol 2003; 57:600-607.
14. INITIO Trial International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368:287-298.
15. Whitby L, Granger V, Storie I, et al. Quality control of CD4+ T-lymphocyte enumeration: results from the last 9 years of the United Kingdom National External Quality Assessment Scheme for Immune Monitoring (1993-2001). Cytometry 2002; 50:102-110.
16. Burton CT, Nelson MR, Hay P, Gazzard BG, Gotch FM, Imami N. Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol 2005; 142:354-361.
17. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
18. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
19. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
20. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
21. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
22. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31:1482-1487.
23. Kurowski M, Kaeser B, Sawyer A, et al. Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily. Eur J Med Res 2002; 7:453-456.
24. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53:4-9.
25. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivuaine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.